Similar articles

• Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study.

  Schröder FH, Tombal B, Miller K, Boccon-Gibod L, Shore ND, Crawford ED, Moul J, Olesen TK, Persson BE. Schröder FH, et al. BJU Int. 2010 Jul;106(2):182-7. doi: 10.1111/j.1464-410X.2009.08981.x. Epub 2009 Nov 13. BJU Int. 2010. PMID: 19912212 Clinical Trial.
• GnRH Antagonists Have Direct Inhibitory Effects On Castration-Resistant Prostate Cancer Via Intracrine Androgen and AR-V7 Expression.

  Cucchiara V, Yang JC, Liu C, Adomat HH, Tomlinson Guns ES, Gleave ME, Gao AC, Evans CP. Cucchiara V, et al. Mol Cancer Ther. 2019 Oct;18(10):1811-1821. doi: 10.1158/1535-7163.MCT-18-1337. Epub 2019 Jul 24. Mol Cancer Ther. 2019. PMID: 31341032
• A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer.

  Crawford ED, Tombal B, Miller K, Boccon-Gibod L, Schröder F, Shore N, Moul JW, Jensen JK, Olesen TK, Persson BE. Crawford ED, et al. J Urol. 2011 Sep;186(3):889-97. doi: 10.1016/j.juro.2011.04.083. Epub 2011 Jul 23. J Urol. 2011. PMID: 21788033 Clinical Trial.
• Degarelix: a gonadotropin-releasing hormone antagonist for the management of prostate cancer.

  Steinberg M. Steinberg M. Clin Ther. 2009;31 Pt 2:2312-31. doi: 10.1016/j.clinthera.2009.11.009. Clin Ther. 2009. PMID: 20110043 Review.
• Degarelix and its therapeutic potential in the treatment of prostate cancer.

  Doehn C, Sommerauer M, Jocham D. Doehn C, et al. Clin Interv Aging. 2009;4:215-23. doi: 10.2147/cia.s3503. Epub 2009 May 14. Clin Interv Aging. 2009. PMID: 19503784 Free PMC article. Review.